DRSP/EE

Phase 1Small molecule

Vertex Pharmaceuticals

DRSP/EE is one of 86 small molecule programs targeting Oral. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OralActive, not recruiting

Autosomal Dominant Polycystic Kidney DiseaseNot yet recruiting

InteractionRecruiting

OralPhase 1

Active, not recruiting

Autosomal Dominant Polycystic Kidney DiseasePhase 1

Not yet recruiting

InteractionPhase 1

Recruiting

Competition

Competitive Landscape

62 competitors in Interaction

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Approved

6 2

Robitussin

Pfizer

Phase 3

10 3

Epsom Salt

FFresenius Kabi USA, LLC

Approved

1 4

Rifadin

Sanofi

Phase 2

34 5

Sporanox

SSebela Pharmaceuticals Development LLC

Phase 2

77 6

Rifampicin

Boehringer Ingelheim

Phase 3

22 7

Crestor

AstraZeneca

Phase 1

61 8

Tegretol

Novartis

Phase 1

16 9

Lanoxin

Oxycontin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Autosomal Dominant Polycystic Kidney Disease

NCT07792408

Clinical

Trials by Indication[1]

Oral1 trial

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

Active, not recruiting· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 1·NCT07074327·74 enrolled

Female1 trial

Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants

Completed· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 1·NCT06820307·50 enrolled

Interaction1 trial

A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants

Recruiting·IInstitut de Recherches Internationales Servier (I.R.I.S.)·Phase 1·NCT07235774·28 enrolled

Autosomal Dominant Polycystic Kidney Disease1 trial

A Phase 1, Open-label Drug Interaction Study to Evaluate the Effect of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives

Not yet recruiting· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 1·NCT07792408·148 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for DRSP/EE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DRSP/EE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DRSP/EE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vertex Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Vertex Pharmaceuticals

DRSP/EE

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Oral1 trial

Female1 trial

Interaction1 trial

Autosomal Dominant Polycystic Kidney Disease1 trial

References

Drug Info

Quick Facts

Related News